We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nuvation Bio Inc (NUVB) USD0.0001 A

Sell:$2.67 Buy:$2.84 Change: No change
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$2.67
Buy:$2.84
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$2.67
Buy:$2.84
Change: No change
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Contact details

Address:
357 Tehama Street, Floor 3
SAN FRANCISCO
94103
United States
Telephone:
+1 (415) 7543517
Website:
https://www.nuvationbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NUVB
ISIN:
US67080N1019
Market cap:
$949.12 million
Shares in issue:
336.57 million
Sector:
Pharmaceuticals
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • David Hung
    President, Chief Executive Officer, Founder, Director
  • Philippe Sauvage
    Chief Financial Officer and Principal Financial Officer
  • Junyuan Wang
    Chief Executive Officer of AnHeart Therapeutics and Director
  • Stacy Markel
    Chief People Officer
  • Moses Makunje
    Principal Accounting Officer, Vice President - Finance
  • Gary Hattersley
    Chief Scientific Officer
  • David Hanley
    Chief Technical Operations Officer
  • David Liu
    Chief Medical Officer
  • Colleen Sjogren
    Chief Commercial Officer
  • Kerry Wentworth
    Chief Regulatory Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.